Printer Friendly

Kava hepatic toxicity. (Clinical Capsules).

Kava-containing dietary supplements have been linked to 10 cases of liver failure requiring transplantation, the Centers for Disease Control and Prevention reported.

Eight weeks after starting use of the supplement, a previously healthy 45-year-old U.S. woman had nausen and weakness. She took rabeprazole for 4 days after it was prescribed initially for acid reflux symptoms, and quit the supplement. Several days later, hospitalization for jaundice and hepatitis prompted a liver biopsy that identified subfulminant hepatic necrosis (MMWR 51[47]:1065-67, 2002).

A previously healthy 14-year-old U.S. girl had nausea, vomiting , decreased appetite, weight loss, and fatigue at the end of 4 months of intermittent kava use. She developed scleral icterus and acute hepatitis 1 week later. She had markedly abnormal liver-function test and active fulminant hepatitis with extensive centrilobular necrosis. Eight patients in Europe reported similar symptoms after taking kava-containing supplements for from 8 weeks to 12 months; all developed fulminant hepatic failure and later underwent liver transplantation.
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Evans, Jeff
Publication:Internal Medicine News
Article Type:Brief Article
Date:Jan 1, 2003
Previous Article:Flexible sigmoidoscopy risks. (Clinical Capsules).
Next Article:Liver disease in cystic fibrosis. (Clinical Capsules).

Related Articles
Swiss, Germans ban kava; Hepatotoxicity cases cited. (FDA Issues Health Care Alert).
Kava investigation. (Policy Practice).
Kava's source of liver damage pinpointed. (Herbal Anxiolytic).
Continue to warn patients about kava's liver toxicity. (Safer Versions Likely).
Kava banned in the U.K. due to hepatotoxicity. (70 Cases Reported).
Kava formally banned in the U.K. due to hepatotoxicity. (70 Reports of Liver Damage).
Kava-kava: a lesson for the phytomedicine community. (ESCOP Section).
Kava extracts: safety and risks including rare hepatotoxicity.
Kavalactones fail to inhibit alcohol dehydrogenase in vitro.
Hepatocellular toxicity of kava leaf and root extracts.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters